News
Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback